
0:00
7:00
This week's acromegaly literature centers on long-term disease burden — cardiovascular morbidity, musculoskeletal disease, and precision-medicine treatment selection — while the rare disease industry notched a landmark ultra-rare gene therapy approval, a $1.65B radiopharma merger, and a $123M bet on an oral thyroid eye disease pill.
More episodes from "Acromegaly Update"



Don't miss an episode of “Acromegaly Update” and subscribe to it in the GetPodcast app.








